论文部分内容阅读
目的:探讨卡培他滨不同用药方案治疗晚期消化道肿瘤的疗效。方法:84例消化道肿瘤患者随机分为观察组和对照组各42例。观察组,卡培他滨2000mg/m2,2次/d,餐后30min口服,3周为1个周期,4周后重复1个周期治疗。对照组,卡培他滨2500mg/m2,2次/d,餐后30min口服,2周为1个周期,每3周后重复1个周期治疗。结果:观察组总获益31例,总获益率78.81%,与对照组的29例(69.05%)比较差异无统计学意义,P>0.05;观察组有效15例,有效率35.71%,对照组有效13例,有效率30.95,两组比较差异无统计学意义,P>0.05。两组均未发现肝肾功能损害。观察组皮肤色素沉着、手足综合征发生率明显高于对照组,差异有统计学意义,P<0.05。两组恶心呕吐、口腔炎、白细胞下降及腹泻的发生率差异无统计学意义,P>0.05。观察组无患者需要停药或推迟下周期用药时间;对照组中有2例Ⅳ度手足综合征、1例Ⅲ度口腔炎需要暂停用药或推迟下周期用药时间。结论:卡培他滨用于晚期消化道肿瘤,口服用药方便,选择合适的治疗方案,毒副反应较轻,患者耐受性好,对晚期消化道肿瘤仍有治疗价值,可提高患者的生存质量。
Objective: To investigate the curative effect of different capecitabine medication regimens in the treatment of advanced gastrointestinal tumors. Methods: Eighty-four patients with gastrointestinal cancer were randomly divided into observation group and control group, 42 cases each. The observation group, capecitabine 2000mg / m2, 2 times / d, oral 30min after meal, 3 weeks for a cycle, 4 weeks after a repeat treatment. Control group, capecitabine 2500mg / m2, 2 times / d, oral 30min after meal, 2 weeks for a cycle, repeated every 3 weeks after a cycle of treatment. Results: The total benefit of the observation group was 31 cases, the total benefit rate was 78.81%, compared with 29 cases (69.05%) in the control group, the difference was not statistically significant (P> 0.05); the effective rate was 35.71% in the observation group Group effective in 13 cases, the effective rate of 30.95, no significant difference between the two groups, P> 0.05. Liver and kidney dysfunction were not found in both groups. The observation group skin pigmentation, hand-foot syndrome was significantly higher than the control group, the difference was statistically significant, P <0.05. Nausea and vomiting in both groups, stomatitis, leukopenia and diarrhea incidence was no significant difference, P> 0.05. There were no patients in the observation group needed to stop or delay the next cycle of medication; 2 cases of IV hand-foot syndrome in the control group, 1 case of Ⅲ degree stomatitis need to suspend medication or delay the next cycle of medication time. CONCLUSIONS: Capecitabine is used in advanced gastrointestinal tumors. Oral administration is convenient. Choosing the appropriate treatment options with less toxic side effects and patient tolerability is still of therapeutic value for advanced gastrointestinal tumors and can improve patient survival quality.